학술논문

Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease
Document Type
article
Source
Cell. 183(6)
Subject
Biochemistry and Cell Biology
Biological Sciences
Dementia
Neurosciences
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Neurodegenerative
Aging
Brain Disorders
Acquired Cognitive Impairment
Alzheimer's Disease
Aetiology
2.1 Biological and endogenous factors
Neurological
Alzheimer Disease
Case-Control Studies
Cohort Studies
Disease Progression
Humans
Principal Component Analysis
Protein Isoforms
Protein Processing
Post-Translational
tau Proteins
FLEXITau
absolute quantification
disease progression
multiple reaction monitoring
post-translational modifications
prion-like molecules
protein aggregation
proteomics
proteopathy
quantitative mass spectrometry
Medical and Health Sciences
Developmental Biology
Biological sciences
Biomedical and clinical sciences
Language
Abstract
To elucidate the role of Tau isoforms and post-translational modification (PTM) stoichiometry in Alzheimer's disease (AD), we generated a high-resolution quantitative proteomics map of 95 PTMs on multiple isoforms of Tau isolated from postmortem human tissue from 49 AD and 42 control subjects. Although Tau PTM maps reveal heterogeneity across subjects, a subset of PTMs display high occupancy and frequency for AD, suggesting importance in disease. Unsupervised analyses indicate that PTMs occur in an ordered manner, leading to Tau aggregation. The processive addition and minimal set of PTMs associated with seeding activity was further defined by analysis of size-fractionated Tau. To summarize, features in the Tau protein critical for disease intervention at different stages of disease are identified, including enrichment of 0N and 4R isoforms, underrepresentation of the C terminus, an increase in negative charge in the proline-rich region (PRR), and a decrease in positive charge in the microtubule binding domain (MBD).